The gastrointestinal tract is home to millions of microorganisms that collectively form the intestinal microbiota, interacting with the host to maintain homeostasis. Among these microorganisms, Helicobacter pylori (H. pylori) is one of the most prevalent and widely studied bacteria. The World Health Organization (WHO), in 1994, classified H. pylori as a class I carcinogen due to its strong association with gastric cancer (Blanchard and Czinn, 2017). H. pylori is a microaerophilic, gram-negative bacterium that colonizes the gastric mucosa in a spiral configuration. Humans are the exclusive host and reservoir for this bacterium, and its prevalence is particularly high in socioeconomically disadvantaged regions, with infection rates exceeding 80% in some areas (Coelho et al., 2018). H. pylori disrupts the gastric mucosal barrier and produces vacuolating cytotoxin, which contributes to the pathogenesis of various gastrointestinal diseases, including peptic ulcer disease and gastric cancer (Malfertheiner et al., 2012). In recent years, studies have also identified extra-gastrointestinal manifestations of H. pylori infection, such as iron deficiency anemia (IDA) (Kato et al., 2022), vitamin B12 deficiency, and idiopathic thrombocytopenic purpura (Robinson and Atherton, 2021).

Anemia is also recognized by the WHO (Zinebi et al., 2017) as one of the top ten global health issues, affecting approximately one-third of the world’s population, with more than half of these cases attributed to IDA (Lopez et al., 2016). In 2016, anemia affected 41.7% of children under 5 years old, 40.1% of pregnant women, and 32.5% of non-pregnant women globally (WHO, 2022a,b). The WHO has prioritized anemia as a global health issue, aiming to reduce its prevalence among women by 50% by 2025. The clinical manifestations of anemia are primarily due to the reduced capacity of blood to carry oxygen. This reduction is influenced by changes in total blood volume and the respiratory system’s compensatory mechanisms. The most common systemic symptom of anemia is fatigue. Typical signs include pallor of the skin and mucous membranes, dyspnea, loss of appetite, and changes in urine output. Additional manifestations can include pica, alopecia, nail pitting, and atrophic glossitis (Ganz, 2019; Di Angelantonio et al., 2017). Iron deficiency (ID), characterized by reduced systemic iron levels, is the most common micronutrient deficiency worldwide. It is also the primary cause of IDA. Populations at higher risk for ID include children, premenopausal women, and individuals in low-and middle-income countries (GBD 2016 Disease and Injury Incidence and Prevalence Collaborators, 2017; Santos et al., 2020). ID disrupts oxygen transport and impairs enzymatic reactions in various metabolic pathways, leading to decreased hemoglobin levels and, ultimately, anemia.

H. pylori infection and its relationship with IDA involve complex and multifactorial mechanisms (Marignani et al., 1997; Barabino et al., 1999). Firstly, H. pylori infection induces gastric mucosal inflammation and disrupts gastric acid secretion (Sato et al., 2015; Annibale et al., 2020; Kishikawa et al., 2020). Gastric acid is essential for the dissolution and absorption of non-heme iron (Flores et al., 2017; Flores et al., 2015), and H. pylori infection often leads to hypochlorhydria or reduced gastric acid secretion, hindering the conversion of dietary iron into its absorbable form (Capurso et al., 2001; Annibale et al., 2003). In addition to impairing iron absorption, H. pylori itself competes with the host for iron, which is crucial for its growth and survival. In a low-acid environment, H. pylori utilizes specialized iron uptake systems to extract iron from the host (Yokota et al., 2013; Lee et al., 2009). This competition depletes the host’s iron reserves and prompts the host to increase the synthesis of hepcidin, further suppressing iron absorption and transport (Mendoza et al., 2019). However, H. pylori has evolved mechanisms to evade immune surveillance, enabling it to continuously extract iron, further reducing iron bioavailability and eventually leading to the onset of IDA.

Previous studies (Muhsen and Cohen, 2008; Qu et al., 2010; Hudak et al., 2017) have largely focused on the general population and have not conducted in-depth research specifically on the pediatric population. The benefits of H. pylori eradication in children remain controversial. It is well known that active eradication therapy is typically not recommended for children infected with H. pylori. This therapeutic strategy is based on the premise that the natural course of H. pylori infection in children is relatively slow, and most children are able to clear the infection on their own as they grow older. However, this approach may result in some untreated children carrying H. pylori into adulthood, potentially increasing their risk of developing extragastric diseases, such as IDA. Currently, in children, there is a lack of comprehensive and systematic reviews or meta-analyses exploring the relationship between H. pylori infection and IDA. To fill this gap, we conducted a meta-analysis aimed at evaluating the association between H. pylori infection and IDA, exploring potential links, and elucidating the clinical value of early eradication of H. pylori. Therefore, whether eradicating H. pylori can bring benefits to the pediatric population becomes the central focus of our research. Our study emphasizes the widespread health impacts of H. pylori infection, particularly in children, where early intervention and eradication strategies are crucial. Through effective eradication measures, the incidence of systemic diseases, including IDA, may be prevented or significantly reduced, ultimately improving the overall health of children.

As of August 9, 2024, a comprehensive search was conducted by four independent authors (WZT, TWT, XHH, and HJL) to identify relevant English-language publications. The search covered the following databases: OVID Medline, Cochrane Library, PubMed, EMBASE, and Web of Science. The focus of the search was on studies reporting the prevalence of H. pylori, IDA, ID and anemia in children and adolescents aged 0 to 20 years. The search was performed using the following keywords: “iron deficiency,” “anemia,” “iron deficiency anemia,” “hemoglobin,” “ferritin,” “iron reserves,” “Helicobacter pylori,” “H. pylori” and “campylobacter pylori,” “children,” and “child.” Examples of the search strategies are provided in Appendix 1–5.

Studies were excluded based on the following criteria: (1) duplicate reports, case reports or series, letters to the editor, comments, or author responses; (2) studies that did not meet the inclusion criteria described below.

To ensure methodological rigor and minimize bias, studies were included if they met the following criteria: (1) data collection based on local hospital surveys; (2) inclusion of general population samples, rather than specific volunteer groups; (3) use of clear, validated blood tests to diagnose ID, IDA and anemia; and (4) confirmation of H. pylori infection through validated diagnostic methods such as carbon-13 breath tests, H. pylori stool tests, or gastric mucosal biopsy specimens.

We excluded factors that could potentially influence the accuracy of H. pylori testing, such as the certain use of proton pump inhibitors (PPIs), opioids, dietary modifications, physical activity, irritable bowel syndrome, gastrointestinal surgery, intestinal motility disorders, diverticulosis, systemic sclerosis, and hypothyroidism. No geographical restrictions were applied to the inclusion criteria.

As the first step, the database search was filtered to identify publications whose titles were relevant to the study hypothesis. The selected publications were then screened based on their abstracts, followed by a full-text review to assess their eligibility for inclusion. Any discrepancies or disagreements regarding eligibility were resolved through discussion and consensus among the three independent reviewers.

We developed Tables 1, 2 to systematically summarize the data from each study, including the study title, author names, publication date, participant demographics, study location, H. pylori infection testing methods, iron status markers, and the classifications for ID, IDA, and anemia. Additionally, we recorded the results and any adjustments made for confounding factors. For each study, we extracted the number of individuals infected with H. pylori, as well as the number of cases of IDA, ID and anemia. For studies reporting relative risk (RR) or odds ratio (ORs), along with their 95% confidence intervals (CIs) or p-values, we used these data directly from the original articles. When these statistics were not provided, we applied appropriate statistical methods to calculate them. In randomized controlled trials (RCTs), we extracted data on the number of participants in both the intervention and control groups, and recorded the mean and standard deviation (SD) of ferritin and hemoglobin levels at both baseline and follow-up.

This meta-analysis includes cross-sectional, cohort, and case–control studies. Eligible studies are summarized, and relevant data are presented in tables. We assessed heterogeneity using the I²statistic, with statistical significance of heterogeneity evaluated through a chi-square test (p < 0.05). The I² values were interpreted as follows: 0–25% indicated no significant heterogeneity, 26–50% indicated low heterogeneity, 51–75% indicated moderate heterogeneity, and values greater than 75% suggested high heterogeneity. A fixed-effects model was used when I² was less than 50%, and a random-effects model was applied when I² exceeded 50%. To further explore potential sources of heterogeneity, we conducted meta-regression analyses. This allowed us to examine how study-level characteristics (e.g., study design, sample size, geographical location, or other relevant covariates) might explain variation in effect sizes across studies. Publication bias was assessed using a funnel plot, and subgroup analyses were conducted by study design (i.e., cross-sectional, cohort, and case–control studies). Sensitivity analyses were performed by excluding individual studies to assess the stability of the results and the impact on heterogeneity. In the meta-analysis of RCTs, we compared the effect sizes of changes in ferritin and hemoglobin levels. We assumed a correlation of 0.5 between baseline and follow-up ferritin and hemoglobin levels. Participants were grouped according to their treatment regimen: those who received H. pylori eradication therapy combined with iron supplementation were compared with those who received H. pylori eradication therapy alone. Additionally, participants who received both anti-H. pylori therapy and iron supplementation were compared with those who received iron supplementation alone. The standardized mean difference (SMD) was calculated using a random-effects model. All statistical analyses were performed using RevMan 5 (version 5.1, Cochrane Collaboration) and STATA (version 17.0, United States).

Three independent researchers (WZT, TWT, and HJL) assessed the quality of the included studies using the Newcastle-Ottawa Quality Assessment Scale (NOS). Different criteria were applied depending on the type of study. For cohort studies, the NOS evaluation focused on several aspects, including: (1) the representativeness of the exposed cohort, (2) the appropriate selection of the non-exposed cohort, (3) the suitability of the exposure factor, (4) the clarity of outcome measures (which did not need to be observed at the study’s onset), (5) the comparability of the exposed and non-exposed groups in terms of design and statistical analysis, (6) the adequacy of outcome evaluation, (7) the duration of follow-up after the outcome, and (8) the adequacy of follow-up for both exposed and non-exposed groups. For case–control studies, the NOS evaluation included: (1) the appropriateness and representativeness of the cases, (2) the selection and appropriateness of the control group, (3) the comparability of cases and controls in terms of design and statistical analysis, (4) the accuracy of exposure factor determination, (5) the consistency of methods used to assess exposure in both cases and controls, and (6) ensuring that the non-response rate was similar between the case and control groups. The maximum score on the NOS scale was 9, with scores of 6–8 indicating good quality. For RCTs, we applied the quality assessment framework proposed by the Cochrane Collaboration. All relevant data from the included studies were systematically compiled into Tables 1, 2. Potential biases identified during the quality assessment process are also highlighted in these tables.

Our meta-analysis included eight cross-sectional studies (Mendoza et al., 2019; Zhang et al., 2022; Muhsen et al., 2009; Christofides et al., 2005; Pacey et al., 2011; Mehata et al., 2021; Zamani et al., 2011; Seo et al., 2002) and three clinical and interventional trial studies (Baggett et al., 2006; DiGirolamo et al., 2007; Liu et al., 2024). The results showed an increased likelihood of developing ID in individuals with evidence of H. pylori infection compared with uninfected individuals, with OR = 1.52 (p < 0.00001, 95% CI 1.32–1.74, I² = 44%) (Figure 2). There was significant heterogeneity between studies, with moderate heterogeneity between studies. Sensitivity analyses suggest that the study by Mehata et al. (2021) led to this heterogeneity. Analysis excluding these studies showed no significant heterogeneity, with OR = 1.65 (p < 0.00001, 95% CI 1.41–1.93, I² = 24%).

A summary analysis was conducted on seven studies (Mendoza et al., 2019; Zhang et al., 2022; Baggett et al., 2006; Liu et al., 2024; Haghi-Ashtiani et al., 2008; Bazmamoun et al., 2014; Lupu et al., 2022) to explore the correlation between H. pylori infection and IDA. The results indicated that individuals infected with H. pylori had a higher likelihood of developing IDA compared to those not infected, with an OR of 1.83 (p = 0.05, 95% CI 1.01–3.33, I² = 67%) (Figure 3). The initial analysis showed significant heterogeneity between studies. After excluding the study by Lupu et al. (2022), heterogeneity decreased, yielding an I²of 37%.

A pooled analysis of eight studies (Christofides et al., 2005; Pacey et al., 2011; DiGirolamo et al., 2007; Haghi-Ashtiani et al., 2008; Baysoy et al., 2004; Al-Sinani et al., 2014; Abdelaziz et al., 2021; Taye et al., 2015) examined the association between H. pylori infection and the occurrence of anemia. The results showed no significant difference in the likelihood of anemia between patients with H. pylori infection and those without, with an OR of 0.94 (p = 0.64, 95% CI 0.73–1.21, I² = 96%) (Figure 4). There was significant heterogeneity among the studies.

To identify the sources of heterogeneity in the association between H. pylori infection and IDA, we conducted a meta-regression analysis considering factors such as age, gender, geographical region (developed vs. developing), and ethnicity. The results of the meta-regression indicated that age was the primary source of heterogeneity (p = 0.044) (Table 3). Specifically, younger individuals infected with H. pylori were more likely to develop IDA. This finding aligns with the objectives of our study and further supports the conclusions drawn from our analysis.

Currently, the commonly used methods for eradicating H. pylori include quadruple therapy, which consists of a PPI, two antibiotics, and a gastric mucosal protective agent. In some regions, simpler triple therapy is also employed, along with the latest medications such as Potassium-Competitive Acid Blocker. The success rate of H. pylori eradication is influenced by various factors, including patient resistance, medication compliance, and regional differences. Typically, the eradication rate falls within the range of 80 to 90%. Our meta-analysis additionally evaluates the impact of H. pylori eradication therapy on iron reserves in children. Children constitute the primary focus of our research, and the included patients are those diagnosed with ID, IDA or anemia. Our study ultimately included five RCTs (Fagan et al., 2009; Duque et al., 2010; Cardenas et al., 2011; Xia et al., 2012; Choe et al., 1999). We compare the changes in hemoglobin concentration and ferritin concentration to reflect whether receiving treatment to eradicate H. pylori affects the patient’s iron reserves. Participants were classified based on their treatment regimen: those who received both H. pylori eradication therapy and iron supplementation were compared with those who received only H. pylori eradication therapy. Furthermore, participants who received both anti-H. pylori therapy and iron supplementation were compared with those who received iron supplementation alone.

Summary analysis indicated that, compared with the H. pylori eradication group alone, the ferritin level in the combined H. pylori eradication and iron supplementation group was slightly increased, SMD = 1.04 (p = 0.17, 95% CI −0.45–2.54, I² = 94%). Significant heterogeneity was observed between the groups (Figure 5). However, when comparing the group receiving both iron therapy and H. pylori eradication to the subsidized treatment group alone, significant increase in ferritin levels was found, SMD = 0.57 (p < 0.0001, 95% CI 0.29–0.86, I² = 0%). Additionally, when the two treatments were combined, there was a statistically significant difference in ferritin levels, with SMD of 0.86 (p = 0.02, 95% CI 0.14–1.57, I² = 89%).

Analysis of hemoglobin results showed that, compared with the H. pylori eradication group alone, there was no significant change in hemoglobin levels in the combined H. pylori eradication and iron supplementation group, SMD = 0.53 (p = 0.22, 95% CI −0.31–1.36, I² = 84%). High heterogeneity was observed within the groups (Figure 6). Similarly, there was no significant increase in hemoglobin levels in the group receiving both iron therapy and H. pylori eradication compared with the group receiving iron supplementation alone, SMD = 0.31 (p = 0.11, 95% CI −0.07–0.69, I² = 29%). Additionally, significant difference in hemoglobin levels was observed when the effects of both treatments were combined, SMD = 0.47 (p = 0.04, 95% CI 0.01–0.93, I² = 75%).

Funnels were constructed based on effect estimates and accuracy for each study to assess the presence of publication bias (Figures 7, 8). The graph is relatively symmetrical, but there are still partly favorable factors for publication.

This study systematically integrated data including a total of 13,573 pediatric patients from 16 regions, representing three ethnic groups, with ages under 20. Our core findings reveal a significant positive association between H. pylori infection and both ID and IDA, while no statistically significant association was found with the overall incidence of anemia. These results provide new evidence to better understand the systemic impact of H. pylori infection, particularly its role in iron metabolism and deficiency. In the meta-analysis of ID, the combined OR = 1.52 (95% CI 1.32–1.74), indicating a 52% increased risk of ID in individuals infected with H. pylori compared to uninfected individuals. Although moderate heterogeneity (I² = 44%) was observed, sensitivity analysis showed that excluding the study by Mehata et al. (2021) significantly reduced the heterogeneity to I² = 24%, while strengthening the effect size to OR = 1.65, further confirming the robustness of the original findings. Regarding the association with IDA, the combined OR = 1.83 (95% CI 1.01–3.33), demonstrating a stronger effect. This finding aligns with previous mechanistic studies, which suggest that H. pylori may exacerbate ID through multiple pathways, including impaired iron absorption due to decreased gastric acid secretion, elevated hepcidin levels induced by chronic inflammation, and bacterial iron acquisition mechanisms that deplete host iron stores. Importantly, our study found no significant association between H. pylori infection and overall anemia (OR = 0.94, p = 0.64), despite high heterogeneity (I² = 96%). This apparent contradiction may stem from differences in the types of anemia included in the studies. Specifically, in non-IDA, the anemia-inducing effect of H. pylori may be overshadowed by other underlying causes. This highlights the importance of precise classification in anemia etiology research and suggests that the anemia-inducing mechanisms of H. pylori are specific to iron metabolism. In conclusion, H. pylori infection is significantly positively associated with IDA in children, with the effect mediated through multiple mechanisms impacting iron metabolism.

In addition, our study observed that H. pylori infection exerts a more indirect or less significant influence on anemia. This result is consistent with our initial expectations. We believe this is due to the varying underlying causes of anemia. Chronic anemia, for instance, is frequently associated with systemic chronic inflammation and immune responses rather than solely with disorders of iron absorption and utilization (Gallagher, 2022). In such cases, inflammatory cytokines, including tumor necrosis factor-alpha and interleukin-6, stimulate hepatic iron regulation, thereby reducing iron release and utilization (Raj, 2009). This leads to iron “sequestration” within the body, where iron reserves remain adequate, yet the iron cannot be efficiently transported to the bone marrow, ultimately resulting in anemia. Aplastic anemia (Young, 2018), on the other hand, typically arises from insufficient bone marrow hematopoietic function or abnormalities in hematopoietic stem cells. The direct relationship between local gastric inflammation caused by H. pylori infection and bone marrow hematopoietic function appears to be minimal, rendering H. pylori infection’s impact on this type of anemia relatively insignificant. Additionally, H. pylori infection may indirectly impair iron metabolism by altering the gut microbiota composition (Chen et al., 2021). Disruptions to intestinal health, particularly to the integrity of the intestinal barrier, could further hinder iron absorption. However, the extent of this effect on non-IDA, such as chronic anemia, remains uncertain and warrants further investigation. In summary, while H. pylori infection plays a critical role in the pathogenesis of IDA, its effects on other forms of anemia are more complex and often indirect. Non-iron-deficiency anemias, such as chronic anemia or aplastic anemia, frequently involve broader systemic immune responses or bone marrow dysfunction, processes that H. pylori infection influences only under specific conditions. Further studies are required to elucidate these nuanced interactions and better understand the broader implications of H. pylori infection in anemia subtypes.

To further investigate the sources of heterogeneity in the association between H. pylori infection and IDA, we conducted a meta-regression analysis that included potential confounders such as age, gender, region (developed vs. developing), and ethnicity. Our regression analysis revealed that age is a significant factor contributing to the observed heterogeneity. This finding aligns with our research objectives and provides further support for the strong association between H. pylori infection and IDA, particularly in children (Milman et al., 1998). Furthermore, our study suggests that younger patients may be more prone to developing IDA following H. pylori infection. There are several potential reasons for this observed relationship. First, the gastrointestinal system of young children is still developing and not yet fully matured. As such, it is more susceptible to gastric mucosal inflammation and reduced gastric acid secretion caused by H. pylori infection (Kostaki et al., 2003). Since iron absorption predominantly occurs in the small intestine and gastric acid plays a crucial role in the dissolution and absorption of iron, young children are at a higher risk of developing IDA due to the impaired absorption of iron (Chen et al., 2021). Second, compared to adults, children—especially infants and toddlers—have lower iron reserves. Consequently, any factors that impair iron absorption or increase iron loss will have a more pronounced effect on their iron status, making them more vulnerable to IDA (Queiroz et al., 2024). Third, the typical diet of young children, which is often primarily based on breast milk or formula, may not provide sufficient iron to meet their needs. This can further exacerbate ID (Goddard et al., 2011). Taken together, these factors suggest that young children are particularly vulnerable to the negative effects of H. pylori infection on iron absorption. Their developing immune and gastrointestinal systems, coupled with lower iron stores, increase their susceptibility to IDA.

Notably, our meta-analysis revealed no significant associations between H. pylori-IDA interactions and gender, geographic region, or ethnicity. The relationship between H. pylori infection and IDA exhibits regional variations influenced by socioeconomic and environmental factors. In developing countries, higher H. pylori prevalence (attributed to inadequate sanitation, contaminated water sources, and overcrowded living conditions) interacts synergistically with malnutrition and low dietary iron intake, exacerbating iron absorption impairments and IDA risk (Li et al., 2023). Conversely, developed nations demonstrate lower infection rates and better nutritional status, potentially mitigating H. pylori’s hematological consequences (Sitas et al., 1992). However, our findings do not align with the aforementioned conclusion. This apparent homogeneity may stem from three methodological considerations: First, the predominance of studies from developed regions created sampling bias, potentially underrepresenting socioeconomic heterogeneity within developing nations. Second, while infection rates remain elevated in low-income populations across all regions, this persistent exposure may diminish observable geographic variation. Third, confounding variables such as age-related physiological changes and comorbidities might overshadow regional effects. These findings underscore the necessity for population-specific interventions. Further research employing stratified sampling across socioeconomic subgroups is required to elucidate the complex interplay between environmental determinants and host factors in H. pylori-associated iron metabolism disorders.

Finally, we conducted a summary analysis of changes in ferritin and hemoglobin concentrations following the eradication of H. pylori. The results demonstrated a significant increase in ferritin levels after eradication, indicating an improvement in iron stores. However, the change in hemoglobin concentrations did not reach statistical significance, suggesting that while H. pylori eradication improves iron reserves, its direct impact on hemoglobin levels may be more limited. Several factors may explain this discrepancy. First, ferritin serves as the primary storage form of iron in the body and reflects the level of available iron reserves. After H. pylori eradication, improved iron absorption leads to a rapid restoration of iron stores, as evidenced by the increase in ferritin levels (Mahroum et al., 2022). However, the restoration of hemoglobin concentrations likely requires a longer period of iron supplementation or replenishment, especially in individuals with a history of long-term IDA (Shesh and Connor, 2023). Second, chronic gastritis resulting from H. pylori infection can have lasting effects on iron absorption and utilization. Even after the bacterium is eradicated, the inflammatory state of the gastric mucosa may persist for some time (Homan et al., 2024), potentially accompanied by other gastrointestinal dysfunctions. This ongoing inflammation can continue to impair the effective absorption of iron, thereby limiting hemoglobin synthesis. Finally, while ferritin levels reflect iron storage, the distribution and utilization of iron in the body are regulated by complex mechanisms, including hepcidin, a key regulator of iron homeostasis (Yanatori et al., 2023). After H. pylori eradication, iron absorption may improve rapidly, but the redistribution and utilization of iron for processes like hemoglobin synthesis could take longer to fully reflect. This delayed redistribution may explain why hemoglobin concentrations take more time to respond to the improved iron availability (Zhang et al., 2021; Sharndama and Mba, 2022; Carabotti et al., 2021). In summary, following the eradication of H. pylori, ferritin levels showed a significant increase, which provides further evidence that early eradication of H. pylori can help improve iron stores in the body, particularly in children. This finding suggests that addressing H. pylori infection early may play a crucial role in restoring iron reserve levels and mitigating the risk of IDA in affected populations.

This paper has several notable strengths. It provides a comprehensive review of the relationship between H. pylori infection and ID, IDA, and other types of anemia, systematically analyzing potential mechanisms and impacts. By focusing on the pediatric population, it offers valuable insights into an important yet underexplored group. Additionally, the inclusion of studies from diverse regions enhances the generalizability of the findings and highlights differences in healthcare systems and nutritional statuses across populations. From a mechanistic perspective, the paper explores how H. pylori infection contributes to ID and IDA through its effects on gastric acid secretion, iron absorption, iron metabolism, and gastric mucosal damage. This in-depth analysis advances the understanding of its pathogenic mechanisms. Moreover, the study underscores the importance of early diagnosis and intervention, providing practical guidance for clinical practice and a foundation for future prevention and treatment strategies.

This study highlights a link between H. pylori infection and IDA but has several limitations that warrant further investigation. First, it primarily focuses on the pediatric population, leaving the effects on adults, the elderly, and individuals with chronic conditions underexplored. Second, the absence of bone marrow puncture biopsy, the gold standard for diagnosing ID, may have affected diagnostic accuracy due to its invasive nature. Future studies should address these gaps by increasing sample diversity, utilizing more sensitive and non-invasive diagnostic methods, and considering multi-dimensional influencing factors. Additionally, the moderate quality of included studies, as indicated by NOS scores, underscores the need for well-designed RCTs. These should assess the long-term efficacy and potential risks of H. pylori eradication therapy for IDA. Placebo-controlled trials could clarify the direct impact of eradication on IDA recovery, but ethical concerns must be considered, as H. pylori infection is strongly linked to severe gastrointestinal diseases. Balancing ethical considerations with the need for robust evidence is crucial for advancing our understanding of H. pylori and its role in IDA and related conditions.